GLYXAMBI- empagliflozin and linagliptin tablet, film coated United States - English - NLM (National Library of Medicine)

glyxambi- empagliflozin and linagliptin tablet, film coated

boehringer ingelheim pharmaceuticals, inc. - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u), linagliptin (unii: 3x29zej4r2) (linagliptin - unii:3x29zej4r2) - empagliflozin 10 mg - glyxambi is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see clinical studies (14.2)] . limitations of use glyxambi is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. it may increase the risk of diabetic ketoacidosis in these patients [see warnings and precautions (5.1)] . glyxambi has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using glyxambi [see warnings and precautions (5.2)]. glyxambi is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an egfr less than 30 ml/min/1.73 m2 . glyxambi is likely to be ineffecti

JENTADUETO- linagliptin and metformin hydrochloride tablet, film coated United States - English - NLM (National Library of Medicine)

jentadueto- linagliptin and metformin hydrochloride tablet, film coated

boehringer ingelheim pharmaceuticals, inc. - linagliptin (unii: 3x29zej4r2) (linagliptin - unii:3x29zej4r2), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - linagliptin 2.5 mg - jentadueto is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use jentadueto is not recommended in patients with type 1 diabetes mellitus. jentadueto has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using jentadueto [see warnings and precautions (5.2)]. jentadueto is contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73 m2 ) [see warnings and precautions (5.1)]. - acute or chronic metabolic acidosis, including diabetic ketoacidosis [see warnings and precautions (5.1)]. - hypersensitivity to linagliptin, metformin, or any of the excipients in jentadueto, reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred with linagliptin [see warnings and precautions (5.4) and adverse reactions (6.1

TRADJENTA- linagliptin tablet, film coated United States - English - NLM (National Library of Medicine)

tradjenta- linagliptin tablet, film coated

boehringer ingelheim pharmaceuticals, inc. - linagliptin (unii: 3x29zej4r2) (linagliptin - unii:3x29zej4r2) - linagliptin 5 mg - tradjenta is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use tradjenta is not recommended in patients with type 1 diabetes mellitus as it would not be effective. tradjenta has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using tradjenta [see warnings and precautions (5.1)]. tradjenta is contraindicated in patients with hypersensitivity to linagliptin or any of the excipients in tradjenta, reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred [see warnings and precautions (5.3) and adverse reactions (6)]. risk summary the limited data with tradjenta use in pregnant women are not sufficient to inform of drug-associated risk for major birth defects and miscarriage. there are risks to the mother and fetus associated

JARDIANCE 10 MG Israel - English - Ministry of Health

jardiance 10 mg

boehringer ingelheim israel ltd. - empagliflozin - film coated tablets - empagliflozin 10 mg - linagliptin and empagliflozin - jardiance 10mg is indicated: •to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.•as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus •to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease

JARDIANCE 25 MG Israel - English - Ministry of Health

jardiance 25 mg

boehringer ingelheim israel ltd. - empagliflozin - film coated tablets - empagliflozin 25 mg - linagliptin and empagliflozin - jardiance is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.

SPIOLTO RESPIMAT Israel - English - Ministry of Health

spiolto respimat

boehringer ingelheim israel ltd. - olodaterol as hydrochloride; tiotropium bromide as monohydrate - solution for inhalation - olodaterol as hydrochloride 2.5 mcg; tiotropium bromide as monohydrate 2.5 mcg - vilanterol and umeclidinium bromide - spiolto respimat is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

DUOVENT UDVS NEBULISER SOLUTION Singapore - English - HSA (Health Sciences Authority)

duovent udvs nebuliser solution

boehringer ingelheim singapore pte. ltd. - fenoterol hydrobromide; ipratropium bromide monohydrate 0.52mg/4ml eqv. to ipratropium bromide anhydrous - solution - 1.25 mg/4 ml - fenoterol hydrobromide 1.25 mg/4 ml; ipratropium bromide monohydrate 0.52mg/4ml eqv. to ipratropium bromide anhydrous 0.5 mg/4 ml

Catapres Ampoules 150 micrograms in 1 ml Solution for Injection Ireland - English - HPRA (Health Products Regulatory Authority)

catapres ampoules 150 micrograms in 1 ml solution for injection

boehringer ingelheim international gmbh - clonidine hydrochloride - solution for injection - 150 microgram(s)/millilitre - imidazoline receptor agonists; clonidine

MOBIC TABLET 7.5 mg Singapore - English - HSA (Health Sciences Authority)

mobic tablet 7.5 mg

boehringer ingelheim singapore pte. ltd. - meloxicam - tablet - 7.5 mg - meloxicam 7.5 mg

BERODUAL N METERED DOSE INHALER Singapore - English - HSA (Health Sciences Authority)

berodual n metered dose inhaler

boehringer ingelheim singapore pte. ltd. - fenoterol hbr; ipratropium bromide 21 mcg/dose eqv ipratropium bromide anhydrous - aerosol, spray - 50 mcg/dose - fenoterol hbr 50 mcg/dose; ipratropium bromide 21 mcg/dose eqv ipratropium bromide anhydrous 20 mcg/dose